Jointly developed by Kansas University Medical Center, Osaka University and Augusta University, VR/AI Neuro is intended for the evaluation, diagnosis, and monitoring of neurodegenerative diseases, such as Parkinson’s disease
DiagnaMed has signed an exclusive global license agreement with a non-profit organisation of the University of Kansas, for a novel virtual reality (VR) and artificial intelligence (AI) neurodiagnostic system (VR/AI Neuro).
Under the terms of the agreement, the company will obtain exclusive global rights to develop and market VR/AI Neuro from KU Centre for Technology Commercialisation.
The VR/AI Neuro is intended for the evaluation, diagnosis, and monitoring of neurodegenerative diseases, such as Parkinson’s disease.
It was jointly researched and co-developed by Kansas University Medical Center, Osaka University and Augusta University.
VR/AI Neuro is designed to support the evaluation and diagnosis of neurodegenerative disease.
The system enables clinical and remote neurological diagnosis on a low-cost, portable virtual reality device, to deliver accurate diagnoses in less time, said the company.
DiagnaMed board chairman Fabio Chianelli said: “We are excited to advance the development of a novel virtual reality and artificial intelligence neurodiagnostic system that will aim to change the way neurodegenerative diseases are diagnosed and managed.
“We are focused on developing and commercialising next-generation digital diagnostic tools for brain health in mental health and neurological disorders.
“The VR/AI Neuro system complements our product development programs, including BRAIN AGE and BrainTremor, to ensure a full suite of evaluation solutions for healthcare providers to manage their patient’s conditions effectively.”
DiagnaMed is a Canada-based digital diagnostics and therapeutics company focused on improving brain health for mental health and neurodegenerative disorders.
The company is engaged in developing BRAIN AGE, an electroencephalogram (EEG)-based tool to detect an individual’s brain age, and BrainTremor, a wearable device to detect tremors for Parkinson’s disease and essential tremors.
DiagnaMed said that the new VR/AI Neuro system will complement and strengthen its digital diagnostics brain health solutions, BRAIN AGE and BrainTremor.
Research on the VR/AI Neuro system showed that the interface could prompt five common types of movements usable for evaluation, allowing physicians to confirm three out of four abnormalities.